Am J Transplant, Volume 21, Suppl 3 Archives - Page 120 of 139 - ATC Abstracts

2021 American Transplant Congress
Maternal Perinatal Condition and Neonatal Growth and Development After Renal Transplantation
X. Feng, T. Song, Q. Zhong, J. Zeng, X. Wang, Y. Fan, Z. Huang, T. Lin
Department of Urology, Institute of Urology, Organ Transplantation Center, West China Hospital, Sichuan University, Chengdu, China
*Purpose: Although pregnancy and delivery after kidney transplantation have been reported in many studies , it is still little known about growth and development of…
2021 American Transplant Congress
Clinical Validation and Performance of Donor-Derived Cell-Free DNA in Allograft Rejection
S. Anand¹, A. Pai², J. S. Bromberg³, G. Gupta⁴, I. Moinuddin⁴, T. Alhamad⁵, V. Bowers⁶, S. Ghosh⁷, W. Tian⁷, L. Bu⁸, E. Stites⁹
¹Intermountain Medical Center, Murray, UT, ²University of Texas McGovern Medical School, Houston, TX, ³University of Maryland School of Medicine, Baltimore, MD, ⁴Virginia Commonwealth University, Richmond, VA, ⁵Washington University in St. Louis, St. Louis, MO, ⁶Tampa General Hospital, Tampa, FL, ⁷CareDx, Brisbane, CA, ⁸University of Minnesota, Minneapolis, MN, ⁹University of Colorado, Aurora, CO
*Purpose: Extensive literature regarding the utility of donor-derived cell-free DNA (dd-cfDNA) shares various thresholds for active rejection (AR) based on differing data sets for both…
2021 American Transplant Congress
Detection of Rejection in Kidney Transplant Patients Using an Algorithm That Combines Donor Fraction and Absolute Donor-derived Cell-free DNA
S. Bunnapradist¹, E. Ahmed², M. Maninder², Z. P. Demko², P. R. Billings², H. Tabriziani², P. Gauthier³
¹David Geffen Sch of Med @ UCLA, Los Angeles, CA, ²Natera, Inc., San Carlos, CA, ³Natera, Inc., Los Angeles, CA
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) in the plasma of renal allograft patients is a clinically validated biomarker for allograft injury and rejection. Several dd-cfDNA assays…
2021 American Transplant Congress
Hypercholesterolemia and Donor Age Impaired Capillary Vegf and Nitric Oxide (no) Expression and in Turn Decrease Both Microvascular Density and Tubule Villin Expression in Renal Allografts, Resulting in Poor Graft Survival
B. Ozdemir¹, E. Akcay¹, A. Ok Atilgan¹, M. Haberal²
¹Department of Pathology, Baskent University, Ankara, Turkey, ²Division of Transplantation, Department of General Surgery, Baskent University, Ankara, Turkey
*Purpose: The role of aging and hypercholesterolemia (HC) on endothelial cells (ECs) are not well defined. Aged ECs might produce less NO and VEGF, resulting…
2021 American Transplant Congress
I Would Do Whatever It Took”: Understanding the Motivation, Education and Experiences of Kidney Paired Donation Participants
R. Pines¹, Y. A. Iraheta², L. Ambriz², K. A. Dahmani², E. H. Wood², M. Cooper³, A. D. Waterman²
¹Santa Barbara Cottage Hospital, Santa Barbara, CA, ²UCLA David Geffen School of Medicine, Los Angeles, CA, ³Medstar Georgetown Transplant Institute, Washington, DC
*Purpose: To improve kidney paired donation (KPD) educational programs, we conducted semi-structured interviews to understand motivations of past recipients and donors to participate in KPD,…
2021 American Transplant Congress
Combined Liver-Kidney Transplantation in Adults With End-Stage Liver Disease: Risk Factors in Patients with Chronic Kidney Disease Stages 3-5, Not on Maintenance Dialysis
A. Santos, E. Bueno, M. Leghrouz
University of Florida, Gainesville, FL
*Purpose: We aimed to identify the risk factors for combined liver-kidney transplantation (CLKT) vs. liver transplantation alone (LTA) in end stage liver disease (ESLD) patients…
2021 American Transplant Congress
Early Portal Vein Ligation in the Setting of Shorter Hepatectomy May Contribute to Better Surgical Outcomes in Deceased Donor Liver Transplantation
K. Delvecchio, T. Kitajima, A. Mohamed, S. Yeddula, M. Tayseer, T. Ivanics, K. Collins, M. Rizzari, A. Yoshida, M. Abouljoud, S. Nagai
Henry Ford Hosptial, Detroit, MI
*Purpose: Few published reports have suggested lower blood loss in association with early portal vein ligation (e-PVL) during liver transplantation surgery, however there are currently…
2021 American Transplant Congress
Review of 10-Year Liver Explant Pathology Impact on Outcomes in a Single Center
Y. K. Kwon¹, L. Sher¹, S. Khemichian², J. Kahn², Y. Genyk¹
¹Hepatobiliary and Abdominal Transplant Surgery, University of Southern California, Los Angeles, CA, ²Gastrointestinal and Liver Diseases, University of Southern California, Los Angeles, CA
*Purpose: Explant pathology (EP) is an important prognostic factor after liver transplantation (LT) for hepatocellular carcinoma (HCC). The purpose of this study was to correlate…
2021 American Transplant Congress
Adult Deceased Donor Liver Transplantation with Split Liver Grafts vs Whole Liver Grafts. A Single-Center Experience
P. Vargas¹, C. Argo², H. Zachary², M. Stotts², N. Intagliata², P. Northup², S. Pelletier¹, J. Oberholzer¹, N. Goldaracena¹
¹Transplant Surgery, University of Virginia Health System, Charlottesville, VA, ²Gastroenterology and Hepatology, University of Virginia Health System, Charlottesville, VA
*Purpose: The present study aims to report outcomes of adults following SLT in a single-center and compare this selected group with adults recipients following whole…
2021 American Transplant Congress
Waitlist Outcomes for Exception Candidates Following the Implementation of MMaT/250 Score
T. Ishaque¹, J. G. Wang¹, S. Karhadkar², D. Segev¹, A. B. Massie¹
¹Johns Hopkins Medical Institutions, Baltimore, MD, ²Temple University, Philadelphia, PA
*Purpose: Starting in May 2019, exception points were allocated based on DSA-level median-MELD-at-transplant (MMaT/DSA). In February 2020, the exception point system was further modified based…